{"id":3421,"date":"2026-10-22T17:06:36","date_gmt":"2026-10-22T10:06:36","guid":{"rendered":"https:\/\/naviva.com.vn\/?p=3421"},"modified":"2026-10-22T17:08:22","modified_gmt":"2026-10-22T10:08:22","slug":"measles-mumps-and-rubella-vaccine-mmr-tresivac","status":"publish","type":"post","link":"https:\/\/naviva.com.vn\/en\/measles-mumps-and-rubella-vaccine-mmr-tresivac","title":{"rendered":"Measles, Mumps, and Rubella Vaccine (MMR \u2013 TRESIVAC*)"},"content":{"rendered":"<p><span style=\"color: #000000; font-size: 14pt; font-family: 'times new roman', times, serif;\"><strong>Measles, Mumps, and Rubella Vaccine (MMR \u2013 TRESIVAC)<\/strong> is a live attenuated combination vaccine used to induce active immunity against three infectious diseases: measles, mumps, and rubella. The vaccine is indicated for children aged 12 months to 10 years, helping the body develop specific immune responses against the viruses responsible for these diseases.<\/span><\/p>\n<p><span style=\"color: #000000; font-size: 14pt; font-family: 'times new roman', times, serif;\">MMR \u2013 TRESIVAC is manufactured by Serum Institute of India Pvt. Ltd. (India). It contains live attenuated measles, mumps, and rubella virus strains and is formulated as a lyophilized powder for reconstitution before subcutaneous administration.<\/span><\/p>\n<p><span style=\"color: #000000; font-size: 14pt; font-family: 'times new roman', times, serif;\">This article provides information on the MMR vaccine, including its composition, indications, eligible recipients, dosage, administration, contraindications, warnings, adverse reactions, drug interactions, and storage conditions. The information is compiled from the manufacturer&#8217;s instructions for use.<\/span><\/p>\n<p><span style=\"color: #000000; font-size: 14pt; font-family: 'times new roman', times, serif;\"><a style=\"color: #000000;\" href=\"https:\/\/naviva.com.vn\/wp-content\/uploads\/2024\/11\/MMR.png\"><img loading=\"lazy\" decoding=\"async\" class=\"aligncenter size-full wp-image-3418\" src=\"https:\/\/naviva.com.vn\/wp-content\/uploads\/2024\/11\/MMR.png\" alt=\"\" width=\"1290\" height=\"777\" srcset=\"https:\/\/naviva.com.vn\/wp-content\/uploads\/2024\/11\/MMR.png 1290w, https:\/\/naviva.com.vn\/wp-content\/uploads\/2024\/11\/MMR-300x181.png 300w, https:\/\/naviva.com.vn\/wp-content\/uploads\/2024\/11\/MMR-648x390.png 648w, https:\/\/naviva.com.vn\/wp-content\/uploads\/2024\/11\/MMR-768x463.png 768w, https:\/\/naviva.com.vn\/wp-content\/uploads\/2024\/11\/MMR-160x96.png 160w\" sizes=\"auto, (max-width: 1290px) 100vw, 1290px\" \/><\/a><\/span><\/p>\n<p style=\"text-align: center;\"><span style=\"color: #000000; font-size: 12pt; font-family: 'times new roman', times, serif;\"><em>Image: Measles, Mumps, and Rubella Vaccine (MMR)<\/em><\/span><\/p>\n<p>&nbsp;<\/p>\n<p><span style=\"color: #000000; font-size: 14pt; font-family: 'times new roman', times, serif;\"><strong>Indications and eligible recipients<\/strong><\/span><\/p>\n<p><span style=\"color: #000000; font-size: 14pt; font-family: 'times new roman', times, serif;\">MMR \u2013 TRESIVAC is formulated with the Edmonston-Zagreb strain of measles virus, the Leningrad-Zagreb (L-Z) strain of mumps virus, and the Wistar RA 27\/3 strain of rubella virus, all of which are live attenuated strains.<\/span><\/p>\n<p><span style=\"color: #000000; font-size: 14pt; font-family: 'times new roman', times, serif;\">The measles and rubella viruses are cultured in human diploid cells, while the mumps virus is cultured in fibroblasts derived from specific-pathogen-free (SPF) chicken eggs. The vaccine is lyophilized and supplied with a diluent for reconstitution. The product is presented as a yellowish-white lyophilized cake.<\/span><\/p>\n<p><span style=\"color: #000000; font-size: 14pt; font-family: 'times new roman', times, serif;\">The vaccine meets the relevant World Health Organization (WHO) requirements when tested using the methods described in WHO Technical Report Series No. 840 (1994).<\/span><\/p>\n<p><span style=\"color: #000000; font-size: 14pt; font-family: 'times new roman', times, serif;\">MMR \u2013 TRESIVAC is indicated for children aged 12 months to 10 years.<\/span><\/p>\n<p>&nbsp;<\/p>\n<p><span style=\"color: #000000; font-size: 14pt; font-family: 'times new roman', times, serif;\"><strong>Recommended vaccination schedule:<\/strong><\/span><\/p>\n<ul>\n<li><span style=\"color: #000000; font-size: 14pt; font-family: 'times new roman', times, serif;\"><strong>Dose 1:<\/strong> From 12 months of age.<\/span><\/li>\n<li><span style=\"color: #000000; font-size: 14pt; font-family: 'times new roman', times, serif;\"><strong>Dose 2:<\/strong> At 4\u20136 years of age, or at any time provided that at least 4 weeks have elapsed since the first dose or any previous dose of a live vaccine [2].<\/span><\/li>\n<\/ul>\n<p><span style=\"color: #000000; font-size: 14pt; font-family: 'times new roman', times, serif;\"><strong>Dosage and administration of Measles, Mumps, and Rubella Vaccine<\/strong><\/span><\/p>\n<p><span style=\"color: #000000; font-size: 14pt; font-family: 'times new roman', times, serif;\"><strong>Dosage:<\/strong> 0.5 mL of reconstituted vaccine.<\/span><\/p>\n<p><span style=\"color: #000000; font-size: 14pt; font-family: 'times new roman', times, serif;\"><strong>Route of administration:<\/strong> Subcutaneous injection.<\/span><\/p>\n<p><span style=\"color: #000000; font-size: 14pt; font-family: 'times new roman', times, serif;\">Only the diluent supplied with the vaccine should be used for reconstitution. Do not use the diluent supplied with other vaccines or with MMR vaccines manufactured by other manufacturers.<\/span><\/p>\n<p><span style=\"color: #000000; font-size: 14pt; font-family: 'times new roman', times, serif;\"><strong>Contraindications and warnings<\/strong><\/span><\/p>\n<p><span style=\"color: #000000; font-size: 14pt; font-family: 'times new roman', times, serif;\">Individuals receiving corticosteroids, other immunosuppressive agents, or radiotherapy may not develop an optimal immune response.<\/span><\/p>\n<p><span style=\"color: #000000; font-size: 14pt; font-family: 'times new roman', times, serif;\">Vaccination should not be administered to individuals who have a fever, are pregnant, have an acute infectious disease, leukemia, severe anemia or other serious blood disorders, impaired renal function, decompensated heart disease, or who are receiving gammaglobulin or blood transfusions, or those with known hypersensitivity to any vaccine component.<\/span><\/p>\n<p><span style=\"color: #000000; font-size: 14pt; font-family: 'times new roman', times, serif;\">Vaccination is absolutely contraindicated in individuals with a history of hypersensitivity to neomycin or known hypersensitivity to eggs.<\/span><\/p>\n<p><span style=\"color: #000000; font-size: 14pt; font-family: 'times new roman', times, serif;\">MMR \u2013 TRESIVAC must not be administered to pregnant women because of a potential risk of teratogenic effects, although this risk has not been demonstrated.<\/span><\/p>\n<p><span style=\"color: #000000; font-size: 14pt; font-family: 'times new roman', times, serif;\"><strong>Individuals with immunodeficiency<\/strong><\/span><\/p>\n<p><span style=\"color: #000000; font-size: 14pt; font-family: 'times new roman', times, serif;\">Vaccination is contraindicated in individuals with severe impairment of the immune system due to congenital immunodeficiency, HIV infection, progressive leukemia or lymphoma, malignancies, or treatment with high-dose corticosteroids, alkylating agents, or antimetabolites, as well as in individuals receiving radiotherapy for conditions associated with immunodeficiency.<\/span><\/p>\n<p><span style=\"color: #000000; font-size: 14pt; font-family: 'times new roman', times, serif;\"><strong>Adverse reactions<\/strong><\/span><\/p>\n<p><span style=\"color: #000000; font-size: 14pt; font-family: 'times new roman', times, serif;\">According to the manufacturer&#8217;s information, MMR \u2013 TRESIVAC may cause adverse reactions similar to those reported with measles, mumps, and rubella vaccines administered separately.<\/span><\/p>\n<p><span style=\"color: #000000; font-size: 14pt; font-family: 'times new roman', times, serif;\"><strong>Common adverse reactions<\/strong><\/span><\/p>\n<ul>\n<li><span style=\"color: #000000; font-size: 14pt; font-family: 'times new roman', times, serif;\">Injection-site pain and tenderness: Usually occur within 24 hours and resolve spontaneously within 2\u20133 days.<\/span><\/li>\n<li><span style=\"color: #000000; font-size: 14pt; font-family: 'times new roman', times, serif;\">Low-grade fever: Occurs in approximately 5\u201315% of vaccine recipients, usually 7\u201312 days after vaccination, and lasts 1\u20132 days.<\/span><\/li>\n<li><span style=\"color: #000000; font-size: 14pt; font-family: 'times new roman', times, serif;\">Rash: Occurs in approximately 2% of vaccine recipients, usually 7\u201310 days after vaccination, and lasts approximately 2 days.<\/span><\/li>\n<li><span style=\"color: #000000; font-size: 14pt; font-family: 'times new roman', times, serif;\">Arthralgia and arthritis: May occur after vaccination, particularly in adolescent and adult females who lack pre-existing immunity to rubella.<\/span><\/li>\n<li><span style=\"color: #000000; font-size: 14pt; font-family: 'times new roman', times, serif;\">Other reactions: Parotid gland swelling, lymphadenopathy, myalgia, itching, or general discomfort.<\/span><\/li>\n<\/ul>\n<p><span style=\"color: #000000; font-size: 14pt; font-family: 'times new roman', times, serif;\"><strong>Rare adverse reactions<\/strong><\/span><\/p>\n<ul>\n<li><span style=\"color: #000000; font-size: 14pt; font-family: 'times new roman', times, serif;\">Febrile seizures.<\/span><\/li>\n<li><span style=\"color: #000000; font-size: 14pt; font-family: 'times new roman', times, serif;\">Allergic reactions, such as urticaria, itching, or rash.<\/span><\/li>\n<li><span style=\"color: #000000; font-size: 14pt; font-family: 'times new roman', times, serif;\">Aseptic meningitis.<\/span><\/li>\n<li><span style=\"color: #000000; font-size: 14pt; font-family: 'times new roman', times, serif;\">Transient arthralgia or arthritis.<\/span><\/li>\n<\/ul>\n<p><span style=\"color: #000000; font-size: 14pt; font-family: 'times new roman', times, serif;\">Vaccine recipients should be monitored after vaccination and should promptly inform healthcare professionals if any unusual symptoms or serious adverse reactions occur.<\/span><\/p>\n<p><span style=\"color: #000000; font-size: 14pt; font-family: 'times new roman', times, serif;\"><strong>Drug interactions<\/strong><\/span><\/p>\n<p><span style=\"color: #000000; font-size: 14pt; font-family: 'times new roman', times, serif;\"><strong>Individuals who have received immunoglobulins or blood transfusions:<\/strong> The healthcare provider should be informed before MMR \u2013 TRESIVAC is administered. These products may contain antibodies that can reduce vaccine effectiveness. The recommended interval before vaccination varies depending on the type and dose of the product received.<\/span><\/p>\n<p><span style=\"color: #000000; font-size: 14pt; font-family: 'times new roman', times, serif;\"><strong>Individuals requiring tuberculosis testing:<\/strong> Tuberculin skin testing should preferably be performed before or on the same day as MMR \u2013 TRESIVAC vaccination. If testing is performed after vaccination, it is generally necessary to wait at least 4 weeks to avoid potential interference with the test result.<\/span><\/p>\n<p><span style=\"color: #000000; font-size: 14pt; font-family: 'times new roman', times, serif;\"><strong>Packaging and storage<\/strong><\/span><\/p>\n<p><span style=\"color: #000000; font-size: 14pt; font-family: 'times new roman', times, serif;\">Presentation: One-dose vial supplied with 0.5 mL of diluent.<\/span><\/p>\n<p><span style=\"color: #000000; font-size: 14pt; font-family: 'times new roman', times, serif;\">Storage conditions:<\/span><\/p>\n<ul>\n<li><span style=\"color: #000000; font-size: 14pt; font-family: 'times new roman', times, serif;\">Both the lyophilized vaccine and the reconstituted vaccine must be protected from light.<\/span><\/li>\n<li><span style=\"color: #000000; font-size: 14pt; font-family: 'times new roman', times, serif;\">Store the lyophilized vaccine at 2\u20138\u00b0C.<\/span><\/li>\n<li><span style=\"color: #000000; font-size: 14pt; font-family: 'times new roman', times, serif;\">Store the diluent in a cool place and do not freeze it.<\/span><\/li>\n<\/ul>\n<p><span style=\"color: #000000; font-size: 14pt; font-family: 'times new roman', times, serif;\">Shelf life: 30 months from the date on which the final satisfactory potency test result is obtained, provided the vaccine is stored at 2\u20138\u00b0C.<\/span><\/p>\n<p><span style=\"color: #000000; font-size: 14pt; font-family: 'times new roman', times, serif;\"><strong><em>*MMR vaccine trade name updated to TRESIVAC<\/em><\/strong><\/span><\/p>\n<p><span style=\"color: #000000; font-size: 14pt; font-family: 'times new roman', times, serif;\">Measles, Mumps, and Rubella (MMR) combination vaccine manufactured by Serum Institute of India has been approved for a trade name change from <em>Measles, Mumps and Rubella Vaccine Live, Attenuated (Freeze-Dried)<\/em> to TRESIVAC.<\/span><\/p>\n<p><span style=\"color: #000000; font-size: 14pt; font-family: 'times new roman', times, serif;\">According to the Drug Administration of Vietnam, the existing MMR vaccine name may continue to be used during the designated transition period. After August 6, 2027, MMR vaccine batches imported into Vietnam will carry the updated TRESIVAC name on the packaging and instructions for use, in accordance with the approved changes.<\/span><\/p>\n<p><span style=\"color: #000000; font-size: 14pt; font-family: 'times new roman', times, serif;\">This change represents an update to the product name and should not be interpreted as a change to the vaccine&#8217;s composition, quality, or protective efficacy.<\/span><\/p>\n<p><span style=\"color: #000000; font-size: 14pt; font-family: 'times new roman', times, serif;\"><strong>References<\/strong><\/span><\/p>\n<p><span style=\"color: #000000; font-size: 14pt; font-family: 'times new roman', times, serif;\">[1] Instructions for Use of the Measles, Mumps, and Rubella (MMR) Vaccine, Serum Institute of India Pvt. Ltd.<\/span><\/p>\n<p><span style=\"color: #000000; font-size: 14pt; font-family: 'times new roman', times, serif;\">[2] Vaccination Advisory Letter on the Live Attenuated Measles, Mumps, and Rubella Vaccine, Vaccine and Biological Production Company No. 1 (VABIOTECH).<\/span><\/p>\n<p><span style=\"color: #000000; font-size: 14pt; font-family: 'times new roman', times, serif;\"><em>Disclaimer: This article is for informational purposes only and does not replace medical advice. Vaccination should be preceded by appropriate screening and administered under the direction of qualified healthcare professionals.<\/em><\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Measles, Mumps, and Rubella Vaccine (MMR \u2013 TRESIVAC) is a live attenuated combination vaccine used to induce active immunity against three infectious diseases: measles, mumps, and rubella. The vaccine is indicated for children aged 12 months to 10 years, helping the body develop specific immune responses against the viruses responsible for these diseases. MMR \u2013 [&hellip;] <\/p>\n","protected":false},"author":4,"featured_media":3418,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[25],"tags":[],"class_list":["post-3421","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"acf":[],"_links":{"self":[{"href":"https:\/\/naviva.com.vn\/en\/wp-json\/wp\/v2\/posts\/3421","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/naviva.com.vn\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/naviva.com.vn\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/naviva.com.vn\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/naviva.com.vn\/en\/wp-json\/wp\/v2\/comments?post=3421"}],"version-history":[{"count":2,"href":"https:\/\/naviva.com.vn\/en\/wp-json\/wp\/v2\/posts\/3421\/revisions"}],"predecessor-version":[{"id":3423,"href":"https:\/\/naviva.com.vn\/en\/wp-json\/wp\/v2\/posts\/3421\/revisions\/3423"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/naviva.com.vn\/en\/wp-json\/wp\/v2\/media\/3418"}],"wp:attachment":[{"href":"https:\/\/naviva.com.vn\/en\/wp-json\/wp\/v2\/media?parent=3421"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/naviva.com.vn\/en\/wp-json\/wp\/v2\/categories?post=3421"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/naviva.com.vn\/en\/wp-json\/wp\/v2\/tags?post=3421"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}